News
Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director
Lindus Therapeutics, a next-generation drug development company advancing a portfolio of in-licensed assets, has announced the appointment of Dr. Gillian Cannon to its board of directors as a non-executive director.
Announcing our $18m Series A led by investors Creandum and with participation from Peter Thiel
The funding comes from Spotify-backer Creandum, with participation from PayPal co-founder Peter Thiel and returning investors firstminute, Seedcamp, Hambro Perks, Amino Collective, Page One Ventures and Calm/Storm. Additional investment has been provided by angel investors including Nadav Rosenberg, Kaysan Nikkhah, Trevor Martin, Soraya Darabi, Andrej Steinberg, Tom Krüger and Mithi Thaya.
Lindus Health Named Fierce CRO Award Winner in the Outstanding Patient Recruitment and Retention Category
Lindus Health wins the 2025 Fierce CRO Award for Outstanding Patient Recruitment and Retention, highlighting the innovative use of our PIC technique.
A Fireside Chat with Paul Wicks: How can we make clinical research for digital therapeutics more patient-friendly?
Digital Therapeutics are still a relatively new treatment area and there is a lot to learn about conducting clinical research on them. Find out how Paul Wick's, Digital Health expert, thinks research companies can put the patients first.
.jpeg)
Lindus Health launches with $5m seed round to revolutionise health research
Lindus Health publicly launched today, announcing $5m in seed funding from leading technology and healthcare investors including Firstminute Capital, Presight Capital, Seedcamp, Hambro Perks and Amino Collective.